- Home
- TNMG vs CTMX Comparison
TNMG vs CTMX Comparison
Compare TNMG & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNMG
- CTMX
- Stock Information
- Founded
- TNMG 2023
- CTMX 2008
- Country
- TNMG Japan
- CTMX United States
- Employees
- TNMG N/A
- CTMX N/A
- Industry
- TNMG
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- TNMG
- CTMX Health Care
- Exchange
- TNMG NYSE
- CTMX Nasdaq
- Market Cap
- TNMG 20.1M
- CTMX 444.3M
- IPO Year
- TNMG N/A
- CTMX 2015
- Fundamental
- Price
- TNMG $0.50
- CTMX $2.50
- Analyst Decision
- TNMG
- CTMX Strong Buy
- Analyst Count
- TNMG 0
- CTMX 2
- Target Price
- TNMG N/A
- CTMX $5.00
- AVG Volume (30 Days)
- TNMG 505.1K
- CTMX 2.6M
- Earning Date
- TNMG 08-01-2025
- CTMX 08-07-2025
- Dividend Yield
- TNMG N/A
- CTMX N/A
- EPS Growth
- TNMG N/A
- CTMX 128.27
- EPS
- TNMG N/A
- CTMX 0.49
- Revenue
- TNMG $48,493,897.00
- CTMX $147,557,000.00
- Revenue This Year
- TNMG N/A
- CTMX N/A
- Revenue Next Year
- TNMG N/A
- CTMX N/A
- P/E Ratio
- TNMG N/A
- CTMX $5.15
- Revenue Growth
- TNMG 35.31
- CTMX 23.81
- 52 Week Low
- TNMG $0.26
- CTMX $0.40
- 52 Week High
- TNMG $34.08
- CTMX $3.10
- Technical
- Relative Strength Index (RSI)
- TNMG N/A
- CTMX 57.13
- Support Level
- TNMG N/A
- CTMX $2.15
- Resistance Level
- TNMG N/A
- CTMX $2.44
- Average True Range (ATR)
- TNMG 0.00
- CTMX 0.22
- MACD
- TNMG 0.00
- CTMX -0.03
- Stochastic Oscillator
- TNMG 0.00
- CTMX 41.67
About TNMG TNL MEDIAGENE
TNL Mediagene is principally engaged in digital advertising, integrated marketing, marketing survey, artificial intelligence technology, data analysis, content service platform and production of audio-visual programs. Geographically, the company generates the majority of its revenue from Taiwan.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.